{
    "Patient": {
        "Name": "Michael Hobbs",
        "DOB": "1997-11-07",
        "Sex": "Male",
        "Caseno": "6294",
        "Diagnosis": "Epithelial ovarian carcinoma",
        "Physician": "Dr. Tiffany Lee"
    },
    "specimen information": {
        "primary_tumor_site": "Ovarian",
        "specimen_site": "Peritoneal surfaces",
        "specimen_ID": "1469",
        "CollectedDate": "2024-02-20",
        "ReceivedDate": "2024-02-20",
        "Pathological Diagnosis": "Left breast, central, 12:00, suspicious mass, 12-gauge core needle biopsy: Infiltrating moderately-differentiated mammary carcinoma, grade 2, Nottingham score 6 (architectural grade 3, nuclear grade 2, mitotic figures 1).",
        "Dissection Information": "Molecular testing of this specimen was performed after harvesting of targeted tissues with an approved manual microdissection technique. Candidate slides were examined under a microscope and areas containing tumor cells (and separately normal cells, when necessary for testing) were circled. A laboratory technician harvested targeted tissues for extraction from the marked areas using a dissection microscope."
    },
    "Results with Therapy association": [
        {
            "Biomarker": "ER",
            "Method": "IHC",
            "Analyte": "protein",
            "Result": "Positive | 3+, 100%",
            "Therapy association": [
                "BENEFIT",
                "abemaciclib",
                "palbociclib",
                "ribociclib",
                "endocrine",
                "therapy",
                "everolimus"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "PR",
            "Method": "IHC",
            "Analyte": "protein",
            "Result": "Positive | 2+, 95%",
            "Therapy association": [
                "BENEFIT",
                "abemaciclib",
                "palbociclib",
                "ribociclib",
                "endocrine therapy"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "TMB",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "13 m/Mb High",
            "Therapy association": [
                "BENEFIT",
                "pembrolizumab"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "ERBB2",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative | 0",
            "Therapy association": [
                "LACK OF BENEFT",
                "trastuzumab",
                "ado-trastuzumab emtansine",
                "pertuzumab",
                "fam-trastuzumab deruxtecan-nxki",
                "lapatinib",
                "neratinib",
                "tucatinib"
            ],
            "Biomarker_level": "level 1"
        }
    ],
    "Relevant Biomarkers": [
        {
            "BioMarker": "NOTCH1",
            "Method": "Seq",
            "Analyte": "RNA-Tumor",
            "Result": "Mutation not detected"
        },
        {
            "BioMarker": "PD-L1(SP142)",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Positive| 3+, 63%"
        },
        {
            "BioMarker": "KLF1",
            "Method": "Seq",
            "Analyte": "DNA-Tumor",
            "Result": "Fusion not detected"
        }
    ],
    "Genomic Signatures": [
        {
            "BioMarker": "Microsatellite instability",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "High"
        },
        {
            "BioMarker": "Tumor mutational burden",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "13 mutations/Mb High"
        },
        {
            "BioMarker": "Genomic loss of heterozygosity (LOH)",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "High - 37% of tested genomic segments exhibit LOH"
        }
    ],
    "Genes Tested with Pathogenic Alterations": [
        {
            "Gene": "PDGFRB",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Benign",
            "Protien Alteration": "p.H598T",
            "Exon": 10,
            "DNA Alteration": "c.1820G>T",
            "Allele Frequency %": "36.67"
        },
        {
            "Gene": "JAK2",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Pathogenic",
            "Protien Alteration": "p.R1192P",
            "Exon": 12,
            "DNA Alteration": "c.3260C>T",
            "Allele Frequency %": "19.88"
        },
        {
            "Gene": "FGFR2",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Pathogenic",
            "Protien Alteration": " p.W266*",
            "Exon": 14,
            "DNA Alteration": " c.798G>A",
            "Allele Frequency %": "9.09"
        },
        {
            "Gene": "MTOR",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Likely Benign",
            "Protien Alteration": "p.P95X",
            "Exon": 12,
            "DNA Alteration": "1",
            "Allele Frequency %": "14.91"
        },
        {
            "Gene": "MYD88",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Benign",
            "Protien Alteration": "p.E7K",
            "Exon": 7,
            "DNA Alteration": "c.20A>T",
            "Allele Frequency %": "12.35"
        }
    ],
    "Gene variants of unknown significance": [
        {
            "Gene": "HRAS",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.I543V",
            "Exon": 17,
            "DNA Alteration": "c.1905+1G>A",
            "Allele Frequency %": "2.92"
        },
        {
            "Gene": "FGFR4",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.K741X",
            "Exon": 7,
            "DNA Alteration": "1",
            "Allele Frequency %": "2.31"
        },
        {
            "Gene": "SDHD",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.A572G",
            "Exon": 20,
            "DNA Alteration": "1",
            "Allele Frequency %": "1.23"
        },
        {
            "Gene": "KLF1",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.V49M",
            "Exon": 9,
            "DNA Alteration": "c.145G>A",
            "Allele Frequency %": "2.34"
        },
        {
            "Gene": "MYD88",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.D769Y",
            "Exon": 6,
            "DNA Alteration": "c.2329G>C",
            "Allele Frequency %": "4.75"
        }
    ],
    "Immunohistochemistry results": [
        {
            "Biomarker": "MSH2",
            "Result": "Negative| 2+, 98%"
        },
        {
            "Biomarker": "PD-L1(SP142)",
            "Result": "Negative| 1+, 52%"
        },
        {
            "Biomarker": "PTEN",
            "Result": "Positive| 2+, 25%"
        },
        {
            "Biomarker": "ER",
            "Result": "Negative| 2+, 54%"
        },
        {
            "Biomarker": "MLH1",
            "Result": "Negative| 2+, 20%"
        }
    ],
    "Genes Tested with indeterminate results": [
        "KIT",
        "BRAF",
        "SMO",
        "SIX1",
        "MYCN"
    ],
    "Chemotherapy clinical trials": [
        {
            "Drug class": "Anti hormonal therapy",
            "Biomarker": "ER",
            "Method": "IHC",
            "Analyte": "protein",
            "Investigational agents": [
                "anastrazole",
                "letrozole",
                "exemestane",
                "fulvestrant",
                "tamoxifen",
                "goserelin",
                "leuprolide"
            ]
        },
        {
            "Drug class": "Anti hormonal therapy",
            "Biomarker": "PR",
            "Method": "IHC",
            "Analyte": "protein",
            "Investigational agents": [
                "anastrazole",
                "letrozole",
                "exemestane",
                "fulvestrant",
                "tamoxifen",
                "goserelin",
                "leuprolide"
            ]
        },
        {
            "Drug class": "Anti inflammatory agents",
            "Biomarker": "PIK3CA",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "aspirin"
            ]
        }
    ],
    "Targeted therapy clinical trials": [
        {
            "Drug class": "Akt inhibitors",
            "Biomarker": "ARID1A",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "AZD5363",
                "MK-2206",
                "ipataserib"
            ]
        },
        {
            "Drug class": "immunomodulatory agents",
            "Biomarker": "TMB",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "avelumab",
                "atezolizumab",
                "durvalumab",
                "ipilimumab",
                "nivolumab",
                "pembrolizumab"
            ]
        },
        {
            "Drug class": "PARP inhibitors",
            "Biomarker": "NBN",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "BGB-290",
                "BMN-673",
                "olaparib",
                "rucaparib",
                "talazoparib"
            ]
        },
        {
            "Drug class": "Akt/mTor inhibitors",
            "Biomarker": "PIK3CA",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "AZD5363",
                "BYL719",
                "MK-2206",
                "ipataserib",
                "everolimus",
                "temsirolimus"
            ]
        }
    ]
}